Literature DB >> 20179673

Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses.

Dannie Bernard1, Michael S Ventresca, Laura A Marshall, Carole Evelegh, Yonghong Wan, Jonathan L Bramson.   

Abstract

CD4(+) T cells contribute to the antitumor T-cell response as both effectors that promote tumor rejection and helpers that facilitate the activation of other antitumor effector cells, such as CD8(+) T cells. Maximal engagement of both effector and helper CD4(+) T-cell responses is a desirable attribute of cancer vaccines. We have employed the B16F10 murine melanoma model and a series of recombinant adenovirus (Ad) vaccines expressing mutant forms of the tumor antigen, dopachrome tautomerase, to investigate the relationship between antigen processing and the antitumor CD4(+) T-cell response. Our results have revealed an unexpected dichotomy in the generation of helper and effector CD4(+) T-cell responses where CD4(+) T effector responses are dependent upon protein processing and trafficking, whereas CD4(+) T helper responses are not. The results have important implications for strategies aimed at augmenting antigen immunogenicity by altering intracellular processing and localization.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179673      PMCID: PMC2889742          DOI: 10.1038/mt.2010.30

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  50 in total

Review 1.  Post-translational protein modifications in antigen recognition and autoimmunity.

Authors:  H A Doyle; M J Mamula
Journal:  Trends Immunol       Date:  2001-08       Impact factor: 16.687

2.  An immunodominant MHC class II-restricted tumor antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin.

Authors:  D Golgher; F Korangy; B Gao; K Gorski; E Jaffee; M Edidin; D M Pardoll; T Elliott
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

3.  Diverse roles of conserved asparagine-linked glycan sites on tyrosinase family glycoproteins.

Authors:  Y Xu; S Bartido; V Setaluri; J Qin; G Yang; A N Houghton
Journal:  Exp Cell Res       Date:  2001-07-01       Impact factor: 3.905

4.  Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins.

Authors:  M J Mamula; R J Gee; J I Elliott; A Sette; S Southwood; P J Jones; P R Blier
Journal:  J Biol Chem       Date:  1999-08-06       Impact factor: 5.157

5.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

Authors:  Z Qin; T Blankenstein
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

6.  Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis.

Authors:  H Echchakir; M Bagot; G Dorothée; D Martinvalet; S Le Gouvello; L Boumsell; S Chouaib; A Bensussan; F Mami-Chouaib
Journal:  J Invest Dermatol       Date:  2000-07       Impact factor: 8.551

7.  N-linked carbohydrates in tyrosinase are required for its recognition by human MHC class II-restricted CD4(+) T cells.

Authors:  F Housseau; A Moorthy; D A Langer; P F Robbins; M I Gonzales; S L Topalian
Journal:  Eur J Immunol       Date:  2001-09       Impact factor: 5.532

8.  Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination.

Authors:  O Vidalin; E Tanaka; U Spengler; C Trépo; G Inchauspé
Journal:  DNA Cell Biol       Date:  1999-08       Impact factor: 3.311

9.  Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.

Authors:  Florence R Depontieu; Jie Qian; Angela L Zarling; Tracee L McMiller; Theresa M Salay; Andrew Norris; A Michelle English; Jeffrey Shabanowitz; Victor H Engelhard; Donald F Hunt; Suzanne L Topalian
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-06       Impact factor: 11.205

10.  The central role of CD4(+) T cells in the antitumor immune response.

Authors:  K Hung; R Hayashi; A Lafond-Walker; C Lowenstein; D Pardoll; H Levitsky
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

View more
  3 in total

1.  Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.

Authors:  A J Robert McGray; Robin Hallett; Dannie Bernard; Stephanie L Swift; Ziqiang Zhu; Florentina Teoderascu; Heather Vanseggelen; John A Hassell; Arthur A Hurwitz; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2013-10-23       Impact factor: 11.454

2.  Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients.

Authors:  A J Robert McGray; Dannie Bernard; Robin Hallett; Ryan Kelly; Mayank Jha; Caitlin Gregory; Jennifer D Bassett; John A Hassell; Guillaume Pare; Yonghong Wan; Jonathan L Bramson
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

Review 3.  Oncolytic virus and PD-1/PD-L1 blockade combination therapy.

Authors:  Chun-Yu Chen; Brian Hutzen; Mary F Wedekind; Timothy P Cripe
Journal:  Oncolytic Virother       Date:  2018-07-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.